Valneva Austria
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Valneva Austria sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Valneva Austria: 11 sponsored US clinical trials, none currently recruiting.
Valneva Austria sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Zika Virus Infection, with 2 trials.
Top-decile sponsor footprint
Valneva Austria ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
NCT04838444
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
NCT06334393
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
NCT04786444
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
NCT04546724
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
NCT03576183
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
NCT03382964
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
NCT03425149
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
NCT02316470
Safety Surveillance After Immunization With IXIARO
NCT01335412
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
NCT01246479
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
NCT01047839
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 5 |
Therapeutic Areas
How the Valneva Austria archive is shaped
11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).
Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).
Top condition: Zika Virus Infection (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Valneva Austria: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Valneva Austria sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Valneva Austria page
11 registered trials is a research-attention snapshot, not an endorsement of Valneva Austria or any single study.
- None of Valneva Austria's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Zika Virus Infection is the condition Valneva Austria studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Zika Virus Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Valneva Austria pipeline card: 11 registered trials from official public datasets.Report a data error.